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Abstract
In this thesis, molecular dynamics simulations, molecular docking, and homology
modeling methods have been used in combination to design possible inhibitors as well as to
study the structural changes and function of target proteins related to diseases that today are in
the spotlight of drug discovery. The inwardly rectifying potassium (Kir) channels constitute the
first target in this study; they are involved in cardiac problems. On the other hand, tensin, a
promising target in cancer research, is the second target studied here.
The first chapter includes a brief update on computational methods and the current
proposal of the combination of MD simulations and docking techniques, a procedure that is
applied for the engineering of a new blocker for Kir2.1 ion channels and for the design of
possible inhibitors for Tensin.
Chapter two focuses in Kir ion channels that belong to the family of potassium-selective
ion channels which have a wide range of physiological activity. The resolved crystal structure of
a eukaryotic Kir channel was used as a secondary structure template to build the Kir-channels
whose crystallographic structures are unavailable. Tertiapin (TPN), a 21 a.a. peptide toxin found
in honey bee venom that blocks a type of Kir channels with high affinity was also used to design
new Kir channel blockers. The computational methods homology modeling and protein-protein
docking were employed to yield Kir channel-TPN complexes that showed good binding affinity
scores for TPN-sensitive Kir channels, and less favorable for Kir channels insensitive to TPN

vii

block. The binding pocket of the insensitive Kir-channels was studied to engineer novel TPNbased peptides that show favorable binding scores via thermodynamic mutant-cycle analysis.
Chapter three is focused on the building of homology models for Tensin 1, 2 and 3
domains C2 and PTP using the PTEN X-ray crystallographic structure as a secondary structure
template. Molecular docking was employed for the screening of druggable small molecules and
molecular dynamics simulations were also used to study the tensin structure and function in
order to give some new insights of structural data for experimental binding and enzymatic
assays.
Chapter four describes the conformational changes of FixL, a protein of bradyrhizobia
japonicum. FixL is a dimer known as oxygen sensor that is involved in the nitrogen fixation
process of root plants regulating the expression of genes. Ligand behavior has been investigated
after the dissociation event, also the structural changes that are involved in the relaxation to the
deoxy state. Molecular dynamics simulations of the CO-bound and CO-unbound bjFixL heme
domain were performed during 10 ns in crystal and solution environments then analyzed using
Principal Component Analysis (PCA). Our results show that the diffusion of the ligand is
influenced by internal motions of the bound structure of the protein before CO dissociation,
implying an important role for Arg220. In turn, the location of the ligand after dissociation
affects the conformational changes within the protein. The study suggests the presence of a
cavity close to the methine bridge C of the heme group in agreement with spectroscopic probes
and that Arg220 acts as a gate of the heme cavity.

viii

Chapter 1
Computational Methods

Molecular Dynamics Simulations
The first molecule studied by MD simulations was bovine pancreatic trypsin inhibitor
(BPTI), a protein considered small since it has 58 residues. The simulation was done for 8.8 ps
in vacuum1. The continuously growing computer power nowadays, permits simulations of
bigger systems (104-106 atoms) and simulation times of ns or µs2. Due to this, MD Simulations
have been recognized as a widely used tool to study biomolecular systems. Currently, results of
extended simulation runs can be compared to experimental studies; moreover, the structures that
have been determined by X ray or NMR methods can be improved by MD, which makes it a
complimentary tool.
There are three areas of application of MD simulations; the first one is to give
information about the dynamics on different timescales of biomolecules in their natural
environment, in solution; internal motions, conformational changes or even protein folding
processes, followed by the analysis of the thermal averages of molecular properties including
interaction energies and entropies and finally the exploration of conformational space3,4.
The solvent surrounding the protein has been developed into a more realistic description
that includes explicit solvent molecules around protein, the counterions addition in order to
neutralize the system, a naturalistic treatment of the system boundaries, and a more correct
treatment of long-range electrostatic forces. The effect of the solvent on a protein can also be
1

studied in a simulation to collect information of the biomolecular system such as time-averaged
properties like density, conductivity, and dipole moment4.
Improvement in methologies has been also made. Force field parameters have been
updated and now include many atoms in the periodic table; long range electrostatic interactions
are now considered explicitly and pairwise electrostatic interactions are improved for the effect
of the polarizable surroundings outside a cutoff radious5. In the case of system boundary
conditions, the most used method is periodic boundary conditions since it avoids abrupt borders
with vacuum and works to include artificial periodicity into the system4. Also better algorithms
used to control temperature and pressure have been proposed and currently used by MD
programs6-8.
Prevalent programs to perform MD simulations of biomolecules include Amber9,
CHARMM10, GROMOS11, NAMD12 and Desmond13 among others.

Molecular Docking
Docking involves the process of binding a small molecule to a target protein. Several
factors affect this process making it quite complex; for example, the motion of the ligand and
receptor which affects the possible interactions solvent-receptor-ligand-solvent present according
to the molecular distribution of charges4.
Most common docking programs include, DOCK14, AutoDock15, FlexX16, GOLD17,
GLIDE18, and DOT19 among others.
In the case of GLIDE, the molecular probe that could be a potential drug is searched
using a hierarchical series of filters which give possible sites where the ligand can bind to the
receptor active-site, this finally results in a ligand pose18. The accuracy of the score of a ligand
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pose is based in diverse sets of fields within a grid that represents the shape and properties of the
receptor. The conformation of the ligand is changed in order to search for more suitable
conformations and this together with a heuristic screening eliminates unwanted conformations18.
GLIDE works well for small molecules with a limit of 300 atoms per ligand.
When the ligand is bigger than 300 atoms and the problem requires the docking of a
peptide DOT2.0 can be used. DOT is a shape based molecular docking program that performs a
rigid body search of the ligand molecule (or the mobile molecule), translated and rotated about
the stationary molecule which is the receptor19.

Combining Docking and MD Simulations
In order to have a reliable model of the complex ligand-receptor docking techniques have
recently been combined with MD simulations. Docking is used to search for conformations of
the ligands, and ultimately involves the screening of huge libraries of drug-like compounds in a
short time period. The problem here is that the conformation of the receptor is not allowed to
change in the binding process. In this sense, MD is a tool that can add some flexibility to the
receptor and ligand permitting some adjustment upon the binding event. Figure 1 shows a
scheme for the combination of the techniques in some steps of the drug discovery process4.
Different approaches have been developed for the MD inclusion before or after the docking
process. During the receptor structure preparation multiple conformations of the receptor can be
generated and subsequently subjected to docking as an ensemble20.
Another approach includes so called “soft docking” that consist of allowing the ligand
to “penetrate” the surface of the protein in order to account for localized changes that could
occur in a more flexible environment21. The addition of some flexibility to the side chains in the
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active site after ligand binding, constitute a different approach, here a series of rotamer libraries
are used to search for different conformations of the involved side chains22.

Figure 1 Scheme of the Protocol of a Drug Design Process, when the Structure of the Target is
known or can be modeled4. Brackets include steps that are not always done. Gray shades include
steps in which MD simulations can be performed4.

MD simulations are known to help to refine the resultant docking complexes. The
dynamics can add some flexibility to the receptor and ligand, improving their assembly and
enhancing the intermolecular interactions between them. Moreover, the stability of the complex
structure during a simulation trajectory indicates that the complex is realistic and it was correctly
4

docked. Another important feature of running MD after docking is the interaction of the solvent
with the complex and the solvent molecules effect on the stability of the ligand’s docked pose.
Since most of docking algorithms do not take into account the mobility of the receptor or
the interactions with the molecules in the explicit solvent, MD simulations can be used to
enhance a docking protocol4.

Homology Modeling
When a target protein or enzyme structure is not available experimentally from an X-ray
or NMR experiments, the structure can be predicted using its amino acid sequence and a
structural template from an available experimentally defined structure with high accuracy. The
template must be at least 40% similar to the sequence of interest.
According to reported investigations23, the homology modeling process involves seven
steps, the template recognition and initial alignment followed by the processes of alignment
correction and backbone generation, then the loop and side chain modeling finalizing with the
model optimization and validation23.
In the first step an initial sequence alignment has to be performed, the percentage of
identity between the query sequence and the secondary structure template candidate should be
high enough as shown in Figure 2. A BLAST24 or FASTA25 search can be done in order to find
possible candidates. These programs make a comparison between the sequence of interest and all
sequences of known structures in the PDB bank using a residue exchange matrix and an
alignment matrix23. The results are shown according to the percentage of identity as a list of hits.

5

Figure 2 The Two Zones of Sequence Alignments23

The second step involves the alignment correction where some regions of the sequence
of interest or gaps have to be corrected by examining the secondary structure of the template or
by using multiple sequence alignments.
The third, fourth and fifth steps involve the building of the model considering the
secondary structure of the template, which mean the presence of alpha helices or beta strands, as
well as the modeling of loops.
The optimization of the model that includes the use of MD simulations to perform
minimization of energy or simulated annealing, is performed in order to have more energetically
favorable structures, avoiding atom overlaps.
And finally the model validation which is usually done by methods that evaluate
homology models by checking the stereochemical quality of the new structure, verifying the
accuracy of parameters like bond angles, bond lengths, correctness of amino acid chirality and

6

comparing the different φ and ψ backbone dihedral angles within the new structures to the ones
in the X ray structure.
Homology modeling provides a helpful tool for drug design since unavailable target
structures can be predicted, in order to be subsequently screened against drug-like compounds
and learn about their structures and possible function.
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Chapter 2
Docking of the European Honey Bee Venom Peptide Tertiapin in the Inwardly Rectifying
Potassium (Kir) Channels using Homology Models
Introduction
Inwardly rectifying potassium (Kir) channels are a specific subset of potassium selective
ion channels that show greater flow of ions into rather than out the cell. These channels were
first described as anomalous K+ rectifiers due to the differences they showed with respect
voltage-gated K+ (Kv) channels.1 They play an important role in the maintenance of the resting
membrane potential and in regulation of the duration of the action potential in electrically
excitable cells (i.e. cardiac muscle).2
The structures of Kir channels in general contain a motif of two putative membranespanning domains (TM1 and TM2) (Figure 3). These membranes are attached by an extracellular
pore-forming region (H5), a cytoplasmic amino (NH2)- and carboxy (COOH)- terminal
domains.2 This is known as the elemental portion present in all types of inwardly rectifying
potassium channel. The main function of the H5 region is as “ion-selectivity filter” which
signature sequence T-X-G-Y(F)-G is similar to other K+-selective ion channels.3,4
Kir channels are present in a wide number of cell types: cardiac myocytes5, neurons6,
blood cells7, osteoclasts8, endothelial cells9, glial cells10, epithelial cells11, oocytes12 and
kidneys13. G protein-gated K+ (KG) channels and ATP-sensitive K+ (KATP) channels also show
inward rectification and so belong to the Kir channel family14, 15. Seven Kir subfamilies have
10

been identified (Kir1.x to Kir7.x) (Figure 4). These subfamilies are subdivided into four
functional groups: Classical Kir channels (Kir2.x), G protein-gated Kir channels (Kir3.x), ATPsensitive K+ channels (Kir6.x), and K+-transport channels (Kir1.x, Kir4.x, Kir5.x, and Kir7.x)14.
The fact that the basic Kir channel subunits are highly similar, allows the formation of functional
Kir channels in homotetrameric and heterotetrameric combinations. Usually heteromerization
takes place between members of the same subfamily, an example of that could be the
heterotetrameric complex of Kir3.1 with Kir3.4.1, 2

Figure 3 Membrane Spanning Domains (TM1-TM2).2

The physiological function of the Kir channels relies on regulation of pore opening, ion
flux, and channel localization in the cell.

Ions, polyamines, nucleotides, lipids, and some

intracellular proteins are factors that regulate pore opening and ion flux, interacting with
fundamental elements of the Kir channel. The localization of the channels in specific regions of a
cell, contributes to the different roles of the Kir channels in different tissues, an example of this
could be the apical or basolateral membranes of epithelial cells or pre- or postsynaptic sites in
neurons, they are also involved in a wide number of cardiac and neurological diseases.2
11

Figure 4 Kir-Channels Subfamilies.2

Cs+ and Ba2+ have been identified as generic inhibitors of most Kir channels; usually they
have been used to study their physiological function in native cells and tissues.16 Tertiapin, a
toxin constituent of the honey bee venom, has been reported as a potent inhibitor of Kir1.1 and
Kir3.1/3.4 channels with nanomolar binding affinity. The cardiac Kir3.1/3.4 controls the
pacemaker activity, while the renal Kir1 regulates salt reabsorption. Kir1 has been involved in
genetic defects specifically in the type II Bartter’s syndrome that causes characteristic volume
depletion and hypotension. However, classical Kir2.x channels are insensitive to all the known
Kir channels blockers and are known to be involved in cardiac diseases like the Andersen–Tawil
syndrome.17, 18
The present study is focused on the homology modeling of the extracellular vestibule of
three different Kir channels Kir1.1, Kir2.1 and the heteromer Kir3.1/3.4, using as template the
crystal structure of the chicken Kir2.2 channel (cKir2.2). The models of Kir 1.1 and Kir3.1/3.4
channels have been protein-peptide docked with the solved solution structure of the bee venom
12

peptide tertiapin, the results of the protein-peptide docking simulations were compared to
reported in vitro functional binding data for human Kir3.4 and Kir1.1 channels, and human
Kir2.1 which has very low binding affinity to wild type tertiapin. Kir2.1 is of special interest
since these Kir channels have been involved in cardiac diseases and currently there are not
known inhibitors, so based on the facts that Tertiapin lacks negatively charged residues and
Kir2.1 possess positively charged residues within its vestibule, iterative mutagenesis of tertiapin
was performed to engineer a peptide that docks selectively to Kir2.1, in order to perform the
subsequent synthesis and testing on Kir2.1 channels expressed in vitro using standard
electrophysiological methods.

Homology Modeling Kir Channels
The structures of the extracellular portions of the channels Kir1.1, Kir2.1 and the
heteromeric channel Kir3.1/3.4 were not available so they were built using the 3.1Å crystal
structure of the homomeric form of the Kir2.2 channel as a template (PDB code 3JYC)19 and the
amino acid sequences of Kir1.1, Kir2.1 and Kir3.1/Kir3.4.20 Since the Kir2.2 pdb file included
just only one subunit, the 3 other subunits were built using the symmetry matrix reported in the
pdb file and DeepView/Swiss-pdbViewer21, then the models were prepared using the preparation
wizard of Maestro, version 9.3, Schrödinger22, and later subjected to energy minimization with
MacroModel to reduce any bad contacts . The structure prediction was done by Prime Structure
Predictor of the Schrodinger suite version 3.120.
Kir1.1, Kir2.1 and the heterotetrameric Kir3.1/3.4 turrets were modeled as chimeras on
the intracellular portion of Kir2.2 as Figure 5 shows, with average sequence identities close to
90%.

13

a

b

c

d

Figure 5 Ion Channel Structures with Extracellular Portions in VDW Representation. 5a,
secondary structure template Kir 2.2 ion channel. 5b, Kir 1.1ion channel model. 5c, Kir2.1 ion
channel model. 5d, Kir 3.1/3.4 heteromultimeric ion channel model.
These models were then evaluated, aided by Ramachandran plots with the program
Procheck23, which checks the stereochemical quality of a given protein structure by verifying the
accuracy of parameters like bond angles, bond lengths, correctness of amino acid chirality and
compares the different φ and ψ backbone dihedral angles within the new structures to the ones in
known X-ray structures.
Figure 6 shows that most of the aminoacids in Kir 1.1 ion channel model are located
within favored regions in the Ramachandran plot. The majority of residues are in the alpha helix
(A), beta strand (B) and left alpha helix (L) allowed regions of the plot which indicates that the
model was built correctly. The figures show an improvement after minimization of the modeled
ionchannel, the number of residues in disallowed regions decreases from 13 to 8.
The residue Glycine (shown as triangles) is least restricted since contains just one
hydrogen for its “sidechain”; this is demonstrated in the plot where the area where its dihedrals
14

angles are considered correct is larger. On the other hand, the residue Proline, with its 5membered-ring side chain shows only a small number of possible combinations of ψ and φ.
Other residues that remain in disallowed regions are not part of the binding site.
a

b

Figure 6 Ramachandran Plot of Kir1.1 Ion Channel Model. 6a, before minimization and 6b, after
minimization.
Table 1 Plot Statistics according to Model Minimization (Figure 6)
Residues in most favored regions (A, B, L)
Residues in additional allowed regions (a,b,l,p)
Residues in generously allowed regions (~a,~b,~l,~p)
Residues in disallowed regions
Number of end-residues (exc. Gly and Pro)
Number of glycine residues
Number of proline residues
Total number of residues

1027
118
14
13
40
64
56
1332

87.6%
10%
1.2%
1.2%
-----

1032
116
16
8
40
64
56
1332

88.1%
9.9%
1.4%
0.7%
-----

Ramachandran plots in figure 7 shows a markedly decrease in residues in disallowed
areas from 16 to 5 (Table 2) after minimization of Kir2.1 model. However, the majority of
residues are in allowed regions, which implies that secondary structure of the model is correct.

15

In a like manner, in Figure 8, most of the residues are in the alpha helix (A), beta strand
(B) and left alpha helix (L) allowed regions of the plot which implies models were built correctly
and the residues that fall in the disallowed regions are not part of the extracellular portions of the
ion channel models.
a

b

Figure 7 Ramachandran Plot of Kir2.1 Model. 7a, before minimization and 7b, after
minimization.

Table 2 Plot Statistics according to Model Minimization (Figure 7)
	
  
Residues in most favored regions (A, B, L)
Residues in additional allowed regions (a,b,l,p)
Residues in generously allowed regions (~a,~b,~l,~p)
Residues in disallowed regions
Number of end-residues (exc. Gly and Pro)
Number of glycine residues
Number of proline residues
Total number of residues

Before
1004
83.1%
164
13.5%
24
2%
16
1.4%
8
-64
-44
-1324
--

After
1026
159
18
5
8
64
44
1324

85%
13.2%
1.4%
0.4%
-----
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a

b

Figure 8 Ramachandran Plot of Kir3.1/3.4 Model. 8a, before minimization and 8b, after
minimization.
Table 3 Plot Statistics according to Model Minimization (Figure 8)
Residues in most favored regions (A, B, L)
Residues in additional allowed regions (a,b,l,p)
Residues in generously allowed regions (~a,~b,~l,~p)
Residues in disallowed regions
Number of end-residues (exc. Gly and Pro)
Number of glycine residues
Number of proline residues
Total number of residues

1010
158
8
5
28
60
40
1309

Before
85.5%
13.4%
0.7%
0.4%
-----

After
1016
156
6
3
28
60
40
1309

86%
13.2%
0.5%
0.3%
-----

Docking Wild Type Tertiapin
Tertiapin is a peptide contains 21 amino acids (Figure 9), it has six positively charged
residues, four of which are clustered within the C-terminal half of the polypeptide chain.
Negatively charged residues are totally absent in Tertiapin, and the lysine at the carboxyl end is
in an amide form. It presents four cysteines that form two disulfide bonds. According to solution
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NMR experiments this peptide contains a type-I reverse turn and one α-helix, which are
connected by a loop of an extended β-sheet.24,25
The homology models, free of water were used as a stationary molecules to simulate
docking by Tertiapin (PDB code 1TER)24. The simulation allowed the translational motion of the
peptide which structure was solved by NMR. The PDB file contains 21 snapshots of the peptide
in solution.
The first snapshop of wild tertiapin structure in solution was taken as starting coordinates
to run an MD simulation of 10 ns duration. The simulation was performed with Desmond 3.126
using the OPLS force field27 in order to study the flexibility of the peptide and to obtain a
equilibrated structure of tertiapin for subsequent docking studies.

a

b

Figure 9 a, Tertiapin Structure in New Cartoon Representation showing Disulfide Bonds
between Cysteines. 9b, Tertiapin Structure in VDW Representation showing Positively Charged
Residues in Blue.
In Figure 10, the root mean square fluctuations (RMSF), that measures the deviation
between the position of an atom and a reference position averaged over time, shows that the first
three residues close to the N-terminus are more mobile, which is expected since they are at one
terminus of peptide.

However, the rest of the peptide residues do not show significant
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fluctuations due to the presence of the disulfide bonds, hence low flexibility was shown by the
peptide structure.
Root mean square deviations (RMSD) measures the average distance between the
backbone atoms of superimposed proteins or peptides, these calculations showed equilibration of
Tertiapin structure after MD simulations (Fig 11), the automated docking of the resultant
Tertiapin structure was then performed using the DOT 2.0 software28. The program calculates
partial atomic charges at heavy atoms and polar hydrogens for the moving molecule and uses

RMSF (Å)

programs like REDUCE29 to add hydrogens to all the molecules present in the calculation.

Residues

Figure 10 Residue Mean Square Fluctuations (RMSF) of Tertiapin Structure during 10 ns of
Molecular Dynamics Simulation.
MSMS30 another employed program in DOT calculation, it describes the shape of the
stationary molecule by an excluded volume surrounded by a 3 Å layer, rolling a probe sphere of
radius 1.4 Å. The calculation of the electrostatic potential of the stationary molecule is performed
by APBS31, the calculation is done at heavy atoms and polar hydrogens, restricted to the solvent
surface. Grid size was set to 384 Å, to make sure that under periodic conditions the relatively
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small toxin Tertiapin was not influenced by the shape or electrostatic properties of the large
stationary molecule in adjacent cells. Required grid space was 1 Å. The contacts between the

RMSD (Å)

receptors and the ligand were then calculated using Pymol32.

Time (ns)

Figure 11 Residue Mean Square Deviations (RMSD) of Tertiapin Structure during 10 ns of
Molecular Dynamics Simulation.

Docking with the software DOT was peroformed using 6 degrees of orientational
searching in order to obtain the widest number of samples. All of these resulted in an average of
54,000 placements, which were preferred based on electrostatic and van der Waals terms. DOT
computes two scores directly, electrostatic energy (from the Poisson-Boltzmann electrostatic
model) and pseudo-van der Waals energy. The binding score is sorted on the sum of the two
scores.28 Table 4 presents the resultant binding scores of the docking of Tertiapin in the Kir
channel models 1.1, 2.1 and 3.1/3.4 according to the 6 degrees of rotation of the mobile
molecule, the 10 top ranking placements, evaluated also on the basis of pair wise atomic contact
energy, are shown.
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According to the literature in vitro experiments have shown that Tertiapin (TPN) is a
potent blocker of Kir1.1 and Kir3.1/3.4 channels.

It is been reported that TPN inhibits

homotetrameric Kir1.1 with a Kd of ~1 nM and heterotetrameric Kir3.1/3.4 with ~10-fold lower
affinity. Affinity of the channel for TPN relies in the side chains present in the turrets of the
Kir3.4 portion, while the Kir3.1 turrets have shown to be insensitive towards tertiapin in the
homomeric form25. Table 4 shows that Kir1.1 presents the best binding scores with wild
Tertiapin followed by Kir3.1/3.4 scores. In the case of Kir2.1, the binding scores were the worst
ones as expected, some of the ligand structures were docked within the intracellular portion of
the Ion channel.

Table 4 Binding Scores of Docking Tertiapin in the Kir Channel Models (Kcal/mol).
Kir1.1
-26.5189
-26.0221
-25.4607
-25.2764
-24.9414
-24.8365
-24.8284
-24.7091
-24.4714
-24.4351

Kir2.1
-15.0003
-14.7172
-14.6265
-14.5433
-14.4305
-14.4269
-13.9493
-13.8682
-13.7651
-13.7626

Kir3.1/3.4
-20.7737
-20.7728
-20.7532
-20.6582
-20.6385
-20.4495
-20.2543
-20.2396
-20.2325
-20.2099

The difference between snapshots in Tertiapin structure was also studied; in Figure 12,
the root mean square deviation (RMSD) between the 21 structures was calculated. Two different
groups are defined according to the difference in their conformations. Snapshots 1 and 4 belong
to the first group of conformations; snapshot 16 belongs to the second group, according to
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RMSD calculations. RMSD measures the deviation between the position of an atom and a
reference position taking the average over the particles, giving time specific values.

Figure 12 RMSD Calculations between Snapshots of the NMR Structures of TPN PDB file,
Code 1TER.

These structures were also docked in the Kir1.1 model to study the difference in ligandreceptor interactions with respect to the change in conformation in the ligand, the binding scores
are in the following table.

Table 5 Binding Scores of Docking Tertiapin Different Conformations in the Kir Channel
Models (Kcal/mol).
TPN1
-26.4083
-26.164
-25.9028
-25.656
-25.613
-24.8497
-24.6872
-24.2163
-24.1963
-24.1206

Kir1.1
TPN4
-28.3945
-28.2702
-27.9354
-27.7951
-27.6543
-27.1872
-26.7921
-26.4051
-25.9512
-25.8222

TPN16
-26.4268
-25.4882
-25.2821
-25.1244
-24.7812
-24.7202
-24.7156
-24.4598
-24.4103
-24.2396

TPN1
-14.2853
-

Kir2.1
TPN4
-21.9437
-16.1295
-15.4565
-16.3782

TPN16
-16.6184
-15.9899
-15.8499
-
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Binding scores were similar to the ones already shown; Kir1.1 shows very good binding
scores for all the three cases, with no difference resulting from the change of conformation of
Tertiapin while in the case of Kir2.1 bad docking scores were obtained and in most of the cases
no docking poses were observed in the extracellular portion of the ion channel.

Molecular Dynamics of the Complex
In order to prove stability of the complexes, each one of the ion channel-peptide
coordinates of the complexes that corresponded to the top binding scores were prepared using the
VMD program (Visual Molecular Dynamics version 1.9.1)33 for molecular dynamics simulation.
Simulations were performed with Desmond 3.126 using the OPLS force fields27. Periodic
boundary conditions were used and the initial structure was placed in an equilibrated water box.
To create a neutral simulation box Cl- ions were placed instead of water molecules at the most
positive electrical potential. The system was minimized during 100 ps, then was heated to 300K
during 600 ps and equilibrated at constant volume for 400ps. A standard MD trajectory 10ns
long, at constant pressure and temperature, was performed. The integration time step was 2fs.
Figure 13 shows that the root mean square deviation (RMSD) calculations of the
simulations of the top poses complexes of the Ion channels and Tertiapin structures become
stable after 5 ns of simulation. Simulations were performed to release any overlapping atoms in
the complexes after rigid body docking.
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Figure 13 RMSD Calculation of the Kir Channels-Tertiapin Complex during Molecular
Dynamics Simulations.

Table 6 shows the interactions between the ligand and binding site in the ion channel
models calculated in pymol with list contacts within 3 Å script.
Hydrophobic, Van der Walls and ionic interactions are present between these residues in
receptor and ligand. Kir1.1 shows more interactions with Tertiapin than Kir3.1/3.4. The ionic
interaction between the negative residue Glu83 and positive residues Lys16, Lys17 in tertiapin
are present; also interactions with the phenylalanine ring Phe106, Phe105 and Phe108 in the
center of binding site are seen in table 5. Kir1.1 also interacts with tertiapin through residues
Glu82 and Met13. In the heteromultimeric chimera Kir3.1/3.4, the ligand presents important
interactions just with chains C and D that belong to Kir3.4 extracellular turret in agreement with
experimental studies
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Table 6 Interactions between Kir1.1 and Kir3.1/3.4 Ionchannels and Wild Tertiapin
Ion Channel

Kir1.1

Kir3.1/3.4

Receptor

Ligand

Receptor

Ligand

(A)Phe72
(A)Tyr73
(A)Glu83
(A)Asn84
(A)Tyr104
(A)Gly105
(A)Phe106
(A)Phe106
(A)Phe106
(A)Arg107
(A)Phe108
(A)Phe108
(B)Tyr73
(B)Pro74
(B)Glu83
(B)Gly105
(B)Phe106
(B)Phe108
(C)Tyr73
(A)Lys71
(A)Tyr103
(A)Gly104
(A)Tyr105
(B)Lys71
(B)Lys71
(B)Ala72
(B)Ala72
(B)His73
(B)Val74
(B)Gly104
(B)Tyr105
(C)Val72
(C)Gly73
(C)Asp74

Ala1
Ala1, Pro11
Met13
Ala1, Leu2
Lys17
Met13, Lys17
Leu2, Met13
Cys3, Cys14
Ala1, Pro11
Leu2
Met13
Met13
Gly19
Gly19
Gly19, Lys20
Lys17
Lys16, Lys17
Lys17
His12, Trp15
Ile9, Pro11
Ala1
Leu2
Ala1, Leu2
Cys5, Cys18
Lys17, Gly19
Cys5, Lys20
Cys18
Cys5, Asn6
Asn6
Leu2, Asn6
Cys3, Lys17
Lys16
Lys16
Lys16

(C)Glu83
(C)Asn84
(C)Gly105
(C)Phe106
(C)Phe106
(C)Arg107
(C)Phe108
(D)Tyr73
(D)Tyr73
(D)Pro74
(D)Pro74
(D)Pro74
(D)Asp76
(D)Glu83
(D)Asn84
(D)Tyr104
(D)Gly105
(D)Phe106
(D)Phe108
(C)Ile78
(C)Pro79
(C)Glu83
(C)Asn83
(C)Gly104
(C)Phe105
(C)Thr109
(D)Val
(D)Glu82
(D)Asn83
(D)Gly104
(D)Phe105
(D)Phe105
(D)Phe105
(D)Val107

Lys16
His12, Lys16
Met13, Lys16
Met13, Lys16
His12
Met13
Lys16
Cys5, Asn6
Asn4, Arg7
Cys3,Asn4
Asn6, Arg7
Leu2
Asn4
Cys3
Lys17
Lys17
Lys17
Cys18, Gly19
Leu2
Lys17
Lys17
Lys17
Met13
Leu2
Met13
Lys17
Arg7
Ala1
Ala1, Asn4
Leu2
Ala1, Leu2
Cys3, Asn4
Asn6, Arg7
Ala1, Leu2

On the other hand, Figures 14-16 show the contact maps between Kir1.1 and different
conformations of Tertiapin to compare and study the influence of the conformational variation of
Tertiapin structure in the interactions with the binding site.
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Figure 14 Contact Map of Kir1.1 Bound to Tertiapin Conformation 1.

The interactions of Kir1.1 with TPN1 are mainly in the center of the peptide from
residues Ile10 to Lys16. In this portion of the peptide, important ionic interactions are present
between Glu83 and His12, Lys16 and Lys21. Moreover, hydrophobic interactions are shown
between Phe106 and Pro11, Met13 and Trp15.
The TPN4 conformation shows more interactions including the four chains of Kir1.1,
even though TPN4 binding is oriented the same way that TPN1. The central portion of the
peptide shows ionic and hydrophobic interactions including the same residues in the case of
TPN1 but also interactions of with residues close to the C-terminus of the peptide are shown
along all residues of the binding site.

26

Figure 15 Contact Map of Kir1.1 Bound to Tertiapin Conformation 4.

In Figure 16, interactions between the TPN16 conformation and Kir1.1 are shown,
although in this case the binding scores were as good in TPN1 and TPN4; the interactions show
that the orientation of the peptide is not the same and that the ligand is binding further out the
binding site due to its conformation, this is shown in Figure 17.
Since the Kir1.1 and Kir2.1 turrets share some residues that show interactions with the
central portion of Tertiapin and its positively charged residues, these residues have been included
in the novel peptide that selectively binds to Kir2.1 turrets that has been engineered in order to
propose a possible blocker for this ion channel.
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Figure 16 Contact Map of Kir1.1 Bound to Tertiapin Conformation 16.

Engineering a Peptide Selective for Kir2.1 Ionchannel
Due to the lack of potential blockers for the Kir2.1 channel, and since the affinity of
Kir2.1 for TPN is low, an engineered peptide has been designed to selectively block Kir2.1 and
hopefully obtain better binding affinities.
In order to study the differences and similarities between binding sites, they were
evaluated by Sitemap 2.2, a tool contained in the Maestro Schrodinger suite that identifies
potential binding sites and predicts their druggability. The chosen grid was of 15 site points with
a cut off of 4 Å from the nearest site point.
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Figure 17 Tertiapin Conformation 16 in Kir1.1 Ionchannel: Peptide is not embedded in binding
pocket.
In Sitemap, the calculation is done in three stages, the first involves the search of one or
more regions on the protein surface suitable for binding of the ligand to the receptor; to locate
sites, a grid of points called “site points” is used depending on how close they are to the protein
surface and solvent accessibility34. Sitemap uses the OPLS-2005 force field.35
The second generates contour maps (site maps) divided into hydrophobic and hydrophilic
maps. The hydrophilic maps are further divided into donor, acceptor, and metal-binding regions.
The evaluation stage concludes with the calculation of properties like site score, size, exposure
score, enclosure, contact, hydrophobic/hydrophilic character and donor/acceptor character. These
scores were previously derived running the SiteMap program on several proteins bound to their
inhibitors with potencies in the submicromolar range and executing statistical analyses that
resulted in optimized scores.34
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According to Halgren34 132 is the average number of site points for submicromolar sites,
the druggability score (Dscore) answer the question of whether the site is druggable or not, the
results in the studies by Halgren suggest that a good average for the submicromolar site for site
score is 1.01. The size of a binding site is related to the number of site points contained within a
putative site, exposure scores are considered lower the better, being 0.52 the average for
submicromolar sites while higher enclosure scores are good with an average of 0.76 for
submicromolar sites. In the case of contact score, the average is 1, which is also the average for
the hydrophobic/hydrophilic character and finally for the donor/acceptor character the average
for the submicromolar sites is 0.76.

Table 7 SiteMap Scores for the Binding Sites of Kir1.1 and Kir2.1 Models.
Model

SiteScore

Size

Exposure

Enclosure

HH
character

DA
character

Kir 1.1

0.713

39

0.63

0.703

0.950

0.658

Kir2.1

0.938

178

0.66

0.640

1.235

1.846

V
199.969Å3
486.717Å3

In figure 18 and table 7, the difference between binding sites is observed; Kir1.1 turrets
show a central hydrophobic site corresponding to the central phenylalanine ring reported in the
literature.25 Also two hydrophobic sites in two of the turrets and small hydrophilic regions
around the defined hydrophobic sites.
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a

b

Figure 18 Sitemap Calculations showing Hydrophilic Regions in Red and Hydrophobic
Regions in Blue. 18a, Kir1.1 Ion channel turrets model. 18b, Kir2.1 Ion channel turrets model.

The scoring function used in Sitemap assesses the propensity of a site for ligand binding
and ranks possible binding sites to eliminate those not likely to be pharmaceutically relevant; the
binding site of this Ion channel has a site score of 0.713, on the other hand, Kir 2.1 turrets show a
central hydrophobic region and small hydrophobic and hydrophilic regions spread throughout the
turrets. The Main difference between turrets of Kir1.1 and Kir2.1 models results in wider
hydrophilic sites in the turrets of Kir2.1 ion channel also in a better site score of 0.938. Most of
the scores are close to the averages proposed for Halgren34 except for the donor/acceptor
character of Kir2.1 binding site that is far from the average, this could be a consequence of its
size and volume, which are bigger, compared to Kir1.1 binding site.
The extracellular turrets of the ion channel models were also compared according to the
charge of residues in order to have more insight about binding properties. Figure 19 shows the
binding pocket of Kir2.1, Kir1.1 and Kir3.1/3.4. Kir2.1 turrets differentiate from Kir1.1 and
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Kir3.1/3.4 turrets in the number of positively charged residues present in the surface of binding
pocket.
Based on this fact, positively charged residues in the wild tertiapin (Lys and Arg) have
been mutated to negatively charged residues (Asp and Glu), in order to add selectivity for the
Kir2.1 ion channel to the engineered peptide, possible combinations and their corresponding
binding scores in Kir2.1 are shown in Table 8.

a

b

c

Figure 19 Ionchannel Turrets in VDW Representation Colored according Residue Charge.
Neutral residues in yellow, positively charged residues in blue and negatively charged residues in
red. 19a, Kir1.1 Ionchannel turrets; 19b, Kir3.1/3.4 Ionchannel turrets and 19c, Kir2.1
Ionchannel turrets.

Mutations to negatively charged residues close to the N-terminal of the peptide improve
the binding score in cases of the models 1-4. R7E and R7D mutations show the best scores in
models 7 and 18 respectively, indicating that this position is key in binding to the Kir2.1
Ionchannel. Model 11 shows a good binding score with the K20E additional mutation; however,
the K20D mutation was not energetically favored. Moreover, models 12 and 21 show favorable
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binding scores with the mutation K17E and K17D respectively. A trend regarding the chain size
difference between the two negative residues Asp and Glu was not observed.

Table 8 Binding Scores of the Modeled Peptides in Kir2.1 Ionchannel.
Model
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

Score
-19.8681
-20.8892
-20.6335
-21.2707
-17.0567
-15.0982
-25.0949
-------18.9342
-------22.3594
-21.7680
-17.0128
-------18.0145
-14.9820
-16.0145
-23.3380
-17.0146
-14.0674
-20.6593
-------17.4592
-16.0324
-16.7824
-15.2858

Sequence

Similar interactions are observed between Kir2.1 Ionchannel and peptide models 7 and
11, shown in Table 10. Hydrophobic interactions are present between the phenylalanine ring of
the Ion channel and residues Ile9, Ile10 and Pro11 of the modeled peptides, also van der Waals
interactions with polar residues of the models are shown
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Table 9 Interactions Present between Kir2.1 Ionchannel and the Modeled Peptides 7, 11.
Model

Model 7

Model 11

Receptor
(A)Asp75
(A)Thr78
(A)Ser79
(A)Lys80
(A)Lys80
(A)Ala84
(A)Val86
(A)Ser87
(A)Ser87
(A)Glu88
(A)Glu88
(A)Val89
(A)Asn90
(A)Tyr108
(A)Gly109
(A)Phe110
(A)Arg111
(B)Tyr108
(A)Asp75
(A)Thr78
(A)Ser79
(A)Lys80
(A)Lys80
(A)Ala84
(A)Val86
(A)Ser87
(A)Glu88
(A)Glu88
(A)Val89
(A)Asn90
(A)Tyr108
(A)Gly109
(A)Phe110
(A)Phe110

Ligand
Ala1
Ala1
Ala1,Asn4
Asn4, Glu7
Asn6
Ala1
Ala1
Ala1, Leu2
Pro11
Ala1, Leu2
Met13, Cys14
Leu2
Leu2
Met13
His12, Met13
Met13, Cys3
Met13
His12
Ala1
Ala1
Ala1, Asn4
Asn4, Glu7
Asn6
Ala1
Ala1
Leu2, Pro11
Leu2, Met13
Cys14
Leu2
Leu2
Met13
Met13
Met13, Cys3
Cys14

Receptor
(B)Gly109
(B)Phe110
(B)Phe110
(C)Ser87
(C)Glu88
(C)Glu88
(C)Tyr108
(C)Gly109
(C)Phe110
(C)Phe110
(C)Phe110
(C)Cys112
(D)Ser87
(D)Glu88
(D)Tyr108
(D)Gly109
(D)Phe110
(D)Cys112
(B)Tyr108
(B)Gly109
(B)Phe110
(B)Phe110
(C)Ser87
(C)Glu88
(C)Tyr108
(C)Gly109
(C)Phe110
(C)Phe110
(C)Cys112
(D)Ser87
(D)Glu88
(D)Tyr108
(D)Gly109
(D)Phe110

Ligand
His12, Lys16
His12, Lys16
Trp15, Lys21
Trp15, Lys21
Ile9, Trp15
Lys21
Met13
His12
His12, Trp15
Ile9, Ile10
Pro11
His12, Trp15
Lys17
Lys17
Lys16
Met13, Lys16
Lys16, Lys17
Met13
His12
His12, Lys16
His12, Trp15
Lys16, Lys21
Lys21, Trp15
Trp15, Lys21
Met13
His12
His12, Trp15
Pro11, Ile9
His12, Trp15
Lys17
Lys17
Lys16
Met13, Lys16
Lys16, Lys17

Common residues in the Kir Ionchannels interact with the central portion of the peptides,
as well as in the case of the wild type tertiapin. In this case, ionic interactions are present through
residue Glu88 and residues Lys17, and Lys21.Moreover, mutated residues in modeled peptides
(Glu7) show ionic interactions with residue Lys80. Mutated residue K20E in model 11 is not
interacting with the Kir2.1 ion channel, however importance relays in the mutation R7E, which
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is showing interactions with the receptor. Modeled peptides bind to Kir2.1 ion channel in the
same orientation that wild tertiapin in Kir1.1 ion channel, binding scores improvement is due to
the negative mutated residues in the peptides.

Conclusion and Future Directions
Homology models of Kir1.1, Kir2.1 and Kir3.1/3.4 have been validated using ProCheck
with >85% of residues in A, B and L allowed regions.
The interactions present between the Kir Channel models and the wild type Tertiapin are
in agreement with the reported in experimental results and this also validates the homology
models built.
Docking the engineered peptides in Kir2.1 show good binding results and this suggest
these could be selective Kir2.1 ligands.
Calculations of Potential Mean Force (PMF) using steered Molecular Dynamics
simulations will be used to study more deeply the interactions between the engineered peptides
and the receptor and therefore obtain more selectivity towards the Kir2.1 channels.
The best scores involved in the docking of the mutated peptides in Kir2.1, will be
synthesized and experimentally screened against Kir2.1 using standard in vitro electrophysiology
to test their blocking activity.
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Chapter 3
Docking and Molecular Dynamics Study of TENSIN Homology Models
using PTEN as Template
Introduction
At present, it is well known that the majority of cancers are a consequence of a multistep
genetic process that includes the inactivation of tumor suppressor genes or activation of
oncogenes. As a consequence, apoptosis can be promoted or inhibited1. The PTEN gene is
mutated in many advanced cancers and its name means “phosphatase homology/tensin
homology”.2
PTEN is a ‘dual-specificity’ phosphatase which means that substrates include both
phosphotyrosine and phosphoserine/phosphothreonine.

An example is the vaccinia-related

phosphatase (PDB 1VHR). Before PTEN was discovered, no phosphatase domain was known to
recognize both proteins and lipids3.
The tumor suppressor function of PTEN heavily depends on its lipid phosphatase activity
that involves dephosphorylation of the phosphate from the D3 position of phosphatidylinositol
3,4,5-triphosphate (PIP3)4. PTEN not only inhibits cellular migration and proliferation but also
modulates cell growth and apoptosis5. Moreover, PTEN activity highly relates to other diseases
such as liver diseases, diabetes, etc.6, 7. However, PTEN mechanisms of expression and function
are not clear yet. Currently, many studies suggest that PTEN regulation can occur at the
transcriptional level, as well as post-translationally by phosphorylation, oxidation and
acetylation.
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The structure is composed of two structural domains, the phosphatase (PTP’s) and C2
domains or catalytic domain, Figure 19. C2 domains are lipid binding domains with diverse
primary sequences8.

It is also known that some C2 domains also binds calcium and/or

phosphotyrosine9. The PTEN structure contains the signature motif HCXXGXXR present in the
active sites of protein tyrosine phosphatases (PTPs) which is included in the homology region of
Tensin10.

Figure 20 Molecular Architecture of Different Tensins and PTEN. PTP, C2, SH2 and
PTB correspond to the respective domains whereas ZF zinc finger and AB actin binding
domains.
Tensin is a protein localized in regions of the plasma membrane called focal adhesions,
is widely expressed in human tissues and belongs to the group of tyrosine phosphatases (PTPs),
which remove phosphate from phosphorylated tyrosine residues on proteins. The first tensin
cDNA sequence was isolated from chicken in 1991, and has been predicted to have a molecular
mass of 220 kDa11. Its structure has been characterized through different methodologies11,

12

,

indicating that it could form a dimer, even though the evidence is not yet compelling. Tensin
crystallographic structure is not available. Nonetheless the tensins display a high percentage of
sequence similarity with respect to PTEN. Tensin has been classified as tensin 1, 2, 3 and 4
according to the order of sequence characterization, the first three share PTP, C2, SH2 and PTB
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domains in the same general locations in the gene product as Figure 20 shows, the first two
domains at the N-terminus and the second two at the C-terminus. However Tensin 4 has no
actin-binding region, PTP domain or C2 domain which can lead to the fact that it could compete
with cellular targets of the other tensins via its SH2 and PTB domains {according to D. Haynie
unpublished data}. The SH2 and PTB domains in tensin have been previously studied for
binding activity13, 14.
Recent articles suggest that Tensin SH2 domain is directly linked to cancer15-17; and
although the main role of tensin in angiogenesis remains unclear, it has been discovered that
tumor endothelial marquer 6 is tensin 315. Furthermore, it is been reported that in advanced lung
cancer, breast cancer, and melanoma, endogenous tensin-3 helps to cell migration, anchorageindependent growth, and tumorigenesis18.
The present study is focused in the building of homology models for Tensin 1, 2 and 3 C2
and PTP domains using the PTEN X-ray crystallographic structure as a structural template. The
validated structures were then subjected to docking simulations using molecular docking of
druggable small molecules and molecular dynamics simulations in order to study their structures
and function and give new insights about structural data for the subsequent use for experimental
binding and enzymatic assays.

Alignment of Tensin Sequences
Figure 21 shows the multiple alignments of Tensin sequences most of the substitutions
are conservative in tensin 1, 2 and 3. The high similarity between Tensin sequences suggests that
they emerge from gene duplication of a proto-tensin gene, which itself seems to have arisen from
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a combination of other duplicated genes {according to D. Haynie unpublished data}. However,
small changes in the protein active sites could have functional implications.

Tensin	
  3
Tensin	
  2
Tensin	
  1
Tensin	
  3
Tensin	
  2
Tensin	
  1

Tensin	
  3
Tensin	
  2
Tensin	
  1

Tensin	
  3
Tensin	
  2
Tensin	
  1

Figure 21 Alignment of Tensin 1, 2 and 3. Portions of the sequence within the active site of the
PTP domain, showed in red squares.
The active sites in PTP domain of Tensin share high homology, the signature motif
shared also by PTEN, show conserved glycine residues which are of great importance for the
formation of the characteristic p-loop involved in catalysis, making the active site backbone
more adaptable, more accommodating. Also, cysteine residues present in this binding region of
tensin 2 and 3 are crucial for enzymatic activity through their thiol group; since in tensin 1,
cysteine is mutated to asparigine in the active site region, it is believed that tensin 1 is
enzymatically inactive10. However, this residue could have a significant impact on substrate
recognition.	
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Modeling Tensin
The primary sequences of the tensins share approximately 40% similarity with PTEN and
this includes the PTP and C2 domains. The homology models of tensin 1, 2 and 3 were built
using their amino acid sequences and the X-ray crystal structure of PTEN available in the PDB
bank (code 1D5R) as the structural template19. The structure prediction was done by Prime
Structure Predictor of the Schrodinger suite version 3.120. The homology models were then
stabilized by simulated annealing using Desmond: High-performance molecular dynamics
simulations for biomolecular systems, version 3.121. The aim of simulated annealing is to get a
more relaxed structure performing a simulation during high and low temperatures in order to
make the structures travel from high energy potential minimum to a lower state by crossing
barriers in the free-energy landscape. Temperature is linearly interpolated as a function of time
between adjacent target temperatures and it is controlled by a thermostat. The simulation was
done in 6 stages as Table 9 shows;

the RMSD calculations during simulated annealing in

Figure 23 show that the three tensin models tend to converge to the PTEN structure RMSD,
which indicates that the structures energetically stabilize and are similar to the X-ray structure of
PTEN.
In order to determine the quality of the models, Ramachandran plots were built using the
program Procheck21 that compares the different φ and ψ backbone dihedral angles within the
new structures to the ones in the X-ray structures and checks if the angles are in favored regions
that contain known angle combinations of protein secondary structures.
Figure 23 shows that most of the aminoacids in Tensin 1 model are located within
favored regions in the Ramachandran plot, an improvement resulted after simulated anneling
simulation. The majority of residues are in the alpha helix (A), beta strand (B) and left alpha
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helix (L) allowed regions of the plot which suggests that the model is likely to be a good
representation of the actual structure.

0

200

400

600

800

1000

Figure 22 Root Mean Square Deviations of the Homology Models of Tensin 1, 2 and 3
compared to PTEN Structure.

Table 10 Stages of the Simulated Annealing Simulation.
Time (ps)

30

100

200

300

500

1000

Temperature (K)

10

100

300

400

400

300

As explained in the previous chapter, glycine residues are shown as triangles and their
allowable area is less restricted since contains one hydrogen in its side chain. The case of proline
is different since its 5-membered-ring side chain shows only a very limited number of possible
combinations of ψ and φ. Residues that are in disallowed regions are not part of the binding site.
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a

b

Figure 23 Ramachandran Plot of Tensin 1 Model. 23a, before simulated annealing. 23b, after
simulated annealing.
Table 11 Plot Statistics Before and After Simulated Annealing (Figure 23)
Residues in most favored regions (A, B, L)
Residues in additional allowed regions (a,b,l,p)
Residues in generously allowed regions (~a,~b,~l,~p)
Residues in disallowed regions
Number of glycine residues
Number of proline residues
Total number of residues

Before SA
211
77.3%
52
19%
5
1.8%
5
1.8%
22
-15
-305
--

AfterSA
209
78.6%
45
16.9%
9
3.4%
3
1.1%
22
-15
-305
--

Figure 24 shows residues in the model aligned to PTEN residues; the amino acid type is
conserved which indicates the secondary structure similarity between the structures. A total of
50% of positives and 32% of identities are present in the alignment of tensin1 with PTEN, and
were taken into account to build the model.
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T1
PTEN
TENSIN1
PTEN
T1
PTEN
TENSIN1
PTEN
T1
PTEN
TENSIN1
PTEN
T1
PTEN
TENSIN1
PTEN

Figure 23Alignment
Alignmentof
of Tensin
Tensin 1 model
withPTEN
PTEN
Figure 24 Sequence
(T1) with

The models of Tensin 2 and 3 are similar. Figures 25 and 26, show that most of the
The cases of models of Tensin 2 and 3 are similar. Figures 24 and 25, show that

residues in the structures fall in areas of allowed combination of dihedral angles also suggesting
most of the residues in the structures fall in areas of allowed combination of dihedral

that the model is likely to be a good representation of the actual structure.
angles indicating that models were built correctly.

a

b

Figure 25 Ramachandran Plot of Tensin 2 Model. 25a, before simulated annealing. 25b, after
simulated annealing.
Some glycine residues, shown as triangles in Ramachandran plots, are in disallowed
Figure 24 Ramachandran plot of tensin 2 model.

regions which are acceptable since they are less restricted due to the small size of its side chain.
The percentage of residues in disallowed regions is low and these residues are not part of the
binding site. Improvement after simulated annealing simulation is also shown.
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Table 12 Plot Statistics Before and After Simulated Annealing (Figure 25)

Residues in most favored regions (A, B, L)
Residues in additional allowed regions (a,b,l,p)
Residues in generously allowed regions (~a,~b,~l,~p)
Residues in disallowed regions
Number of glycine residues
Number of proline residues
Total number of residues

a

Before SA
209
78.6
45
16.9
9
3.4
6
1.1
22
-15
-305
--

After SA
229
86%
25
9.4%
9
3.4%
6
1.1%
22
-15
-305
--

b

Figure 26 Ramachandran Plot of Tensin 3 Model. 26a, before simulated annealing. 26b, after
simulated annealing.

Table 13 Plot Statistics (Figure 26)	
  
Residues in most favored regions (A, B, L)
Residues in additional allowed regions (a,b,l,p)
Residues in generously allowed regions (~a,~b,~l,~p)
Residues in disallowed regions
Number of glycine residues
Number of proline residues
Total number of residues

Before SA
208
77.6%
48
18%
6
2.2%
6
2.2
18
-21
-308
--

After SA
216
80.7%
39
14.6%
8
3.4%
4
1.2%
18
-21
-308
--
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its side chain. The percentage of residues in disallowed regions is low and these residues
are not part of the binding site.
In the same way the alignment of Tensin 2 and 3 with PTEN, figures 26 and 27,
show
acid type.
In thelarge
samesimilarity
way, theregarding
alignmentamino
of Tensin
2 and 3 with PTEN, Figures 27 and 28, show
large similarity regarding amino acid type.
PTEN
TENSIN2

PTEN
T2
TENSIN2
PTEN
PTEN
T2
TENSIN2
PTEN

T2
PTEN
TENSIN2
PTEN
T2
PTEN

Figure 26 Alignment of Tensin 2 model with PTEN
Figure 27 Sequence Alignment of Tensin 2 (T2) with PTEN

In order
buildtothe
tensin
2 model,
48% 48%
positives
and 29%and
of identities
with respect
to
Intoorder
build
tensin
2 model,
of positives
29% of identities
with
PTEN respect
were considered
and for
tensin 3and
47%for positives
and 31%
of identities
were
into
to PTEN were
considered
tensin 3 47%
of positives
and 31%
of taken
identities
account.
were taken into account.

PTEN
T3
TENSIN3
PTEN

T3
PTEN
PTEN
TENSIN3
T3
PTEN
PTEN
TENSIN3
T3
PTEN
PTEN
TENSIN3

Figure Figure
28 Sequence
Alignment
of Tensin
3 (T3)with
withPTEN
PTEN
27 Alignment
of Tensin
3 model

Figure 29 shows the final structures of the homology models of Tensin and the structure
from the pdb bank of PTEN. Modeling was successfully achieved since structures are similar,
these models were used to study structure based drug screening to learn more about Tensin
binding and function
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b
a
c

d

Figure 29 Final Structures of the Models. 29a, structure of tumor suppressor PTEN, PDB Code
1D5R in Cartoon Representation. 29b, final tensin 1 model. 29c, final tensin2 model. 29d, final
tensin 3 model.

Tensin as a Potential Target for Drug Discovery
Studies suggest that tensin could link to signal transduction pathways with the
cytoskeleton since it may perform actin-binding and phosphotyrosine-binding activities and also
be a target for tyrosine kinases14. However, these findings are focused on the SH2 domain of
tensin.
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Due to the lack of structural and experimental function data of tensin PTP domain, the
models built were evaluated with the tool SiteMap 2.2 available in the Maestro Schrodinger
suite23 that identifies potential binding sites and predicts their druggability in three different
stages previously explained in chapter 2.
Differences are shown in the maps. In the case of PTEN the known binding site of the so
called P-loop is clearly defined. For tensin the P-loop zone, included in the homology region to
PTEN, is also defined as possible binding site. However in the region of the C2 domain there is a
possible site for ligand binding, which could be an artifact since no binding information is known
about C2 domains so far. These sites were not found in the corresponding domain on PTEN
which could give an insight with further study of the structural difference in tensins.
Comparing the results of the new denoted PTP domain binding sites of Tensin 1, 2 and 3
in Table 13, indicates that binding site in tensin 2 present more volume, similar to PTEN and the
best site score, closest to 1.
Most of the sitemap scores in table 13 are close to the averages proposed for Halgren23.
Different hydrogen bonds donor and acceptor regions are shown, also areas of hydrophobic
interactions are present which are not observed in PTEN, which is reflected in differences in the
hydrophobic and donor/acceptor characters in table 13. The Tensin PTP domain has been shown
to contain a binding site, diverse for each tensin model.
In order to compare the structures of the models and the crystal structure of the template,
these were 3D superposed using the superposition tool of Schrödinger Maestro suite29. Binding
sites of tensin models are similar to PTEN and share residues properties.
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a

b

c

d

Figure 30 Sitemap Calculations. Yellow mesh for hydrophobic maps, blue mesh for hydrogenbond donor maps and hydrogen-bond acceptor map as red mesh. 30a, tensin 1 model. 30b,
tensin 2 model. 30c, tensin 3 model. 30d, PTEN.

Table 14 Sitemap Results for PTP Domain Sites.
Tensin
Model
1
2
3
PTEN

SiteScore

Size

Exposure

Enclosure

0.760
0.959
0.840
0.930

94
94
86
92

0.72
0.67
0.74
0.75

0.697
0.768
0.750
0.744

HH
Character
1.064
1.094
1.045
0.919

DA
Character
0.534
0.162
1.515
0.851

Volume
(Å3)
162.239
176.302
101.871
174.24
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Figure 31-33 show that model and template have binding sites close conformations and
that residues of tensin models have similar properties that those in PTEN. Positively charged
residues are shown in blue, negatively charged residues are shown in red and polar residues
shown in cyan. 	
  

a

c

b

d

Figure 31 Superposition of Model Tensin 1 and PTEN. 31a, binding sites in ribbon
representation. 31b, residues in the binding site in licorice representation. 31c, Van der Walls
surface of the binding sites. 31d, electrostatic surface of the binding sites.
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Electrostatic surface prove the existence of these charges and van der walls
surface shows the possible sites for these interactions. The three models show marked
similarities and slight differences in electrostatic potential surface.

a

c

b

d

Figure 32 Superposition of Model Tensin 2 and PTEN. 32a, licorice representation of the
residues in the binding site. 32b, superposition of binding sites ribbon representation. 32c, Van
der Walls surface of the binding sites. 32d, electrostatic surface of the binding sites.

Models were virtual screened with the druggable compounds present in the National
Cancer Institute (NCI) Diversity set 2, which consists of a small library, that contains about
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2,000 synthetic small molecules known as bio-actives and selected from NCI screening bank of
molecules. 23
This set was developed by the Developmental Therapeutics Program at the NIH/NCI
from compounds in their repository. The compounds of this library, present characteristics of
druggable molecules: rigidity, posses 5 or fewer rotatable bonds, planarity, contain one or fewer
chiral centers and present pharmacologically desirable features.

a

b

c

d

Figure 33 Superposition of Model Tensin 3 and PTEN. 33a, binding sites in ribbon
representation. 33b, residues in the binding site in licorice representation. 33c, Van der Walls
surface of the binding sites. 33d, electrostatic surface of the binding sites.
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Docking studies have been performed using GLIDE 5.8 of Schrodinger25, which
performs high-throughput virtual screening of potential ligands based on binding mode and
affinity for a given receptor molecule. The GlideScore includes the following terms:
GScore = 0.05*vdW + 0.15*Coul + Lipo + Hbond + Metal + Rewards + RotB + Site

Where, vdW is Van der Waals energy, Coul is Coulomb energy, Lipo is the lipophilic
term for hydrophobic interactions, HBond is the hydrogen-bonding term, Metal is the metalbinding term, Rewards are the rewards and penalties for: buried polar groups, hydrophobic
enclosure, correlated hydrogen bonds and amide twists; RotB is the penalty for freezing rotatable
bonds and Site is for polar interactions in the active25.
Table 14 shows the Glide scores for the tensin models and PTEN. Matches are observed
and compound number 78623 was a common compound docked in PTEN, Tensin 2 and 3; on
the other hand, compound number 156939 was a common compound for the three models of
Tensin. Differences in the lipophilic scores regarding hydrophobic interactions are small between
models and PTEN the same in the case of the hydrogen bonding scores. However, van der Walls
interactions energy term shows differences in the case of tensin 3 which involves a more
favorable site for these interactions. Coulomb energy term fluctuates among the different models
which could be due to the presence of several charged residues in binding sites.
Figure 34 shows some of the possible poses of the resultant small molecular probes that
could be potential drugs and the main interactions present with the residues in the binding sites.
Interactions mostly involve the lysines and glycines in P-loop. Cases of Tensin 3 and PTEN are
more similar including glycines in the interactions.

54

a

b

c

d

Figure 34 Interactions of the Residues in the Binding Site of Tensin1 (a), Tensin2 (b), Tensin 3
(c) and PTEN with Potential Drugs. Positively charged residues in blue, negatively charged
residues in red, hydrophobic residues in green, glycines in gray.

In order to prove stability of the complexes, each one of the models of tensin coordinates
of the complexes were prepared using VMD program (Visual Molecular Dynamics version
1.9.1)26 for molecular Dynamics Simulation. Simulations were performed with the NAMD27 and
CHARMM force fields28. Periodic boundary conditions were used placing the initial structure in
an equilibrated water box. Cl- ions were added instead of water molecules at the most positive
electrical potential in order to create a neutral and more realistic box.
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Table 14 Binding Scores of PTEN and Models of Tensin 1, 2 and 3 (Kcal/mol).

Receptor

C number

G Score

lipo

Hbond

Evdw

eCoul

78623	
  

-9.721	
  

-1.545	
  

-0.883	
  

-21.984	
  

-26.985	
  

78623	
  

-9.272	
  

-1.493	
  

-0.826	
  

-22.597	
  

-25.627	
  

36162	
  

-8.462	
  

-2.359	
  

-0.718	
  

-28.171	
  

-12.670	
  

379099	
  

-7.798	
  

-1.376	
  

-1.156	
  

-22.298	
  

-22.023	
  

38743	
  

-7.601	
  

-1.488	
  

-0.904	
  

-27.553	
  

-18.106	
  

117922	
  

-7.556	
  

-2.082	
  

-0.430	
  

-18.503	
  

-22.058	
  

128281	
  

-7.511	
  

-0.808	
  

-0.946	
  

-19.720	
  

-16.895	
  

122131	
  

-7.487	
  

-1.063	
  

-1.275	
  

-18.274	
  

-20.546	
  

7606

-7.189

-1.369

-0.847

-19.216

-15.190

35076

-7.155

-0.471

-0.326

-20.841

-19.456

43546

-7.062

-1.199

-0.405

-17.174

-16.712

156939

-6.973

-0.944

-0.740

-19.875

-16.210

34875

-6.928

-1.312

-0.996

-24.388

-10.467

16736

-6.910

-0.902

-0.842

-31.554

-5.670

659449

-6.891

-1.158

-0.641

-22.558

-19.152

93945

-6.887

-0.976

-0.496

-28.198

-15.549

107022

-7.128

-0.422

-0.307

-13.094

-27.912

156939

-6.791

-0.308

-0.730

-19.649

-21.602

7606

-6.568

-0.197

-0.935

-21.370

-8.009

36914

-6.473

-0.423

-0.466

-19.204

-8.297

14771

-6.387

-0.436

-0.552

-18.293

-9.977

659434

-6.362

-0.519

-0.823

-20.091

-10.116

19108

-6.294

-0.553

-0.974

-27.094

-6.796

78623

-6.243

-0.157

-0.841

-19.486

-14.401

156939

-7.768

-1.527

-0.922

-28.811

-18.248

35676

-7.424

-1.268

-0.720

-30.831

-14.190

36586

-7.350

-0.984

-0.946

-33.977

-13.154

Tensin 3

270063

-7.236

-0.904

-0.958

-35.263

-12.033

	
  

107022

-7.153

-1.688

-0.679

-36.319

-9.566

34875

-7.137

-2.446

-0.436

-38.928

-19.900

78623

-6.999

-2.237

-0.616

-33.529

-11.003

38743

-6.971

-1.625

-0.619

-21.940

-12.951

PTEN	
  

Tensin 1

Tensin 2
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The minimization, heating and equilibration of the system were completed during
1100ps. The system was minimized, then equilibrated at constant volume for 400ps. A standard
MD trajectory 2ns long, at constant pressure and temperature, was performed. The integration
time step was 2fs, Van der Waals interactions were calculated every step (2fs) while
electrostatics interactions were calculated every other step (PME every 4fs), using the multiple
time step method employed by NAMD. The Particle Ewald Mesh (PME) summation for long
range electrostatic interactions was used.
Figure 35 shows the results of the RMSD calculations of the molecular dynamics
simulations of the complexes between Tensin 1, 2 and 3 models with the top docking pose
corresponding to the best binding score. Stability of the complexes is achieved after half of the
simulation has elapsed. The complexes converged in all cases and ligand-receptor interactions
were then evaluated for the matching cases.

Figure 35 RMSD during MD Simulation of Tensin Complexes
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Interactions of PTEN, tensin 2 and tensin 3 with compound number 78623 are in Figure
36. They were drawn using the interaction map tool of Maestro suite of Schrodinger28. The
compound 78623 with molecular formula C13H12N2O6 and the nomenclature 5-amino-2-(5hydroxy-1,3-dioxo-1,3-dihydro-2h-isoindol-2-yl)-5-oxopentanoic

acid,

presents

functional

groups with diverse characteristics for drug discovery.

a

b

c

Figure 36 Ligand-Receptor Interactions Diagram for Compound 78623. 36a, tensin 2 model.
36b, tensin 3 model. 36c, PTEN.
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The phenolate ion shows H-bonds and ionic interactions with positively charged residues
in tensin 2 and 3, also the ring present some exposure to the solvent. In the case of PTEN the
interactions of this portion of the molecule present H-bonds with hydrophobic and polar residues
in the binding site.

Phenols are relatively soluble molecules that are relatively easily

deprotonated and somewhat reactive toward oxidation ; however phenol substructures are part
of numerous drugs such as antipyretics, steroids and analogs of catecholamines30.
A cyclic imide is in the core of the molecule, presenting ionic interactions with positively
charged residues in the binding site of PTEN. In the case of tensin 2 and 3 these interactions are
less marked including one Lys residue in binding region. Most imide-containing drugs are cyclic
imides which are more stable than open-chain imides28. Imides react with nuclophiles faster than
amides, are soluble in polar media since are highly polar. Two more groups are present in the
proposed molecule, an amide group that shows ionic interactions and H-bonds with negatively
charged residues in PTEN and Tensin binding sites and a carboxyl group that presents also ionic
interactions and H-bonds with positively charged residues in the binding site of all the structures.
Amides are a functional group commonly present in living organisms. In that way, unnatural
amides are sufficiently stable to serve as oral drugs and quick enzymatic hydrolysis rarely
occurs30. The case of the carboxyl group is similar since these are found deprotonated and
negatively charged in most parts of the body.

Carboxyl group constitute an important

pharmacophore of drugs like: fibrates, statins, nonsteroidal ant-inflammatory drugs (NSAIDs),
angiotensin-converting enzyme (ACE) inhibitors, and β-lactam and quinolone antibacterials.
Although usually reasonably well absorbed, carboxyl groups have low volumes of distribution
and few cross the blood-brain barrier (bbb)30.
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Figure 36 shows the interaction diagram of the compound 156939 with Tensin 1, 2 and 3
models. Compound number 156939 of molecular formula C15H10N2O6 and the nomenclature
methyl

6-formyl-4,7-dihydroxy-9-oxo-5H-phenazine-1-carboxylate,

is

also

known

as

Lomofungin or Lomondomycin an antibiotic used in the 1970s for fungal infections. Diverse
functional groups are present interacting with tensin 1, 2 and 3 models30.

a
b

c

Figure 37 Ligand-Receptor Interactions Diagram for Compound 156939. 37a, tensin 1 model.
37b, tensin 2 model. 37c, tensin 3 model.
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Methyl paraben or the methyl ester of p-hydroxybenzoic acid interacts with positively
charged residues in the binding pocket of Tensin 1 and 3 through H-bonds. The orientation of the
possible inhibitor in Tensin 3 makes this portion of the molecule the most interacting one,
presenting hydrophobic interactions with several residues in the binding pocket. In tensin 1 and
2 this portion of the molecule is exposed to the solvent. Carboxylic acid esters are often used as
prodrugs for carboxylic acids, phenols or alcohols due to their metabolic lability, they are more
lipophilic than carboxylic acids30.
Moreover, the 2, 4-Dihydroxybenzaldehyde is the portion of the molecule that interacts
with tensin 1 and 2. It forms H-bonds with positively charged residues, acting as H-acceptor, in
the binding pocket as well as with negatively charged residues acting as H-donor. Ionic
interactions are also present with tensin 1 and 2. In the case of tensin 3 is exposed to the solvent
although it forms 2 H-bonds with a polar residue. Aldehydes are highly electrophilic; the formyl
group could react quickly with a nucleophile and also it can be oxidized to an acid or reduced to
an alcohol, however cyclic Aldehydes are sufficiently stable and common substructures for many
drugs30.
A pyrazine molecule that presents just some polar and hydrophobic interactions is the
core of the proposed inhibitor molecule. Even thought the three models of tensin bind the same
compound of the NCI diversity set II, tensin 1 and 2 present similarities when binding this
molecule but tensin 3 present different interactions and orientation, indicating differences in
binding pocket.
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Conclusions and Future Directions
Models of Tensin 1, 2 and 3 were built and represent potential tertiary structures for the
Tensin molecule, similar to PTEN.
Binding sites of Tensin 1, 2 and 3 are represented hydrophobic and hydrophilic maps
further divided into H-donor and H-acceptor maps.
Potential inhibitors for Tensin have been identified by docking studies and resulting
molecules have shown selectivity for Tensin.
Future directions involve the docking of phosphotyrosine and phosphoserine peptides,
known to bond PTEN experimentally, in Tensin using protein-protein docking methods and for
comparison with the results of enzymatic assays in Dr. Haynie research laboratory. Results of
virtual screening will be used to guide high-throughput screening for inhibitors of phosphatase
activity that are selective for PTEN and the various tensins, taking advantage of the structural
similarity between well known PTEN and tensins.
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Chapter 4
Molecular Dynamics Simulations of Deoxy and Carboxy bjFixLH in Crystal and Solution:
Intrinsic Dynamics Affects the Behavior of the Ligand after Dissociation

Introduction
Heme-based sensors are ligand-binding proteins that contain a regulatory heme-binding
domain or subunit that regulates the closest transmitter region of the same protein. Signal
transducing proteins guide adaptive responses to variations in concentrations of diatomic gases
such as O2, CO or NO, that are currently perceived as physiological messengers1,2. The rhizobial
FixL/FixJ two-component system is a model of biological oxygen sensors, main function consist
of detecting low O2 tensions in order to regulate the expression of the genes responsible for
nitrogen fixation in the anaerobic state within plant root nodules3. In FixL, the N-terminal
consists of a heme-sensory domain whose sequence and tertiary structure makes it a member of
the heme-PAS family, whereas, the C-terminal domain belongs to the family of histidine kinases
and its activity is controlled by the heme-sensory PAS domain4. At low O2 tensions, the heme of
the PAS domain is unliganded; the kinase undergoes autophosphorylation and then transfers this
phosphoryl group to its partner, the DNA-binding response regulator FixJ to express the fixK and
nifA genes. At high O2 tensions the heme is oxygen bound and the kinase activity is suppressed5.
The mechanism of ligand recognition and signal transduction of the isolated heme
domain of FixL, derived from Bradyrhizobium japonicum denoted as bjFixLH (Figure 33) has
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been widely investigated by crystallographic studies6-10. The binding of strong field ligands to
bjFixLH leads to the conformational change of the heme iron that causes motion in other parts
of the protein that regulate the activity of the histidine kinase6, 7. Oxygen or cyanide binding to
the bjFixL heme domain involves a change in the heme stereochemistry that produces
conformational changes in the FG loop and in residues distal to the heme in the Hβ and Iβ strands
of the core β sheet of the PAS domain8, 9. The structure of bjFixLH bound to nitric oxide, which
is a potential product of denitrification by Rhizobia11, gives the insight of a structural
intermediate in the heme-driven conformational change8. Carbon monoxide is a weaker inhibitor
of the kinase activity than oxygen. The structural conformation of the FG loop in the CO-bound
protein is different compared to the O2- and CN-bound structures but similar structural changes
are observed in the Hβ and Iβ strands12. Thus, diatomic ligands are divided into strong and weak
inhibitors: O2 and CN- act as strong inhibitors and CO and NO as weak inhibitors. Also, it has
been shown that upon ligand binding, the heme flats driving a change in the position of the heme
propionates6-12. A salt bridge between the Arginine residue at position 220 and the propionate 7
is present in the deoxy bjFixLH structure13. As a consequence, the shift in the position of the
heme propionates reduces the strength of this bond and the Arg220 residue moves into the heme
pocket forming a hydrogen bond with the ligand (O2, CN-), eventually inducing the structural
reorganization responsible for kinase inactivation13,

14

. In the CO-bound FixL structure, an

absence of interaction between the CO ligand and the Arg220 has been reported15, 16, thus, this
residue remains outside of the heme distal pocket and pointing toward the heme propionate 7
group. Another residue that has been related to Arg220 is Arg206, located at the Fα helix and is
considered an important residue in the structural changes related to the signaling mechanism
because it compensates for the negatively charged propionate 7 upon loss of Arg220 in oxy
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structures8, 9. It also becomes bound to HP6 by a salt bridge in CN- structures7; on the other hand,
in a previous experimental study of bjFixLH16, a bond between the side chain Arg206 and
Asp212 has been reported in the deoxy structure, whereas, it becomes disordered after binding of
CO.

a

	
  

b

	
  
	
  

GH Loop

Figure 38 a, Molecular Representation of the Structure of the CO Bound bjFixLH (PDB Code
1lsv). Secondary structure regions within the protein are identified. 33b, CPK graphical
representation of the CO bound bjFixLH heme pocket. Several groups and residues involved in
structural changes are denoted.

Recent experiments obtained after CO photolysis and recombination in bjFixLH using
time-resolved Laue X-ray crystallography shows important conformational changes occurring in
the protein as a consequence of the relaxation of the steric interactions between the bound ligand
and the side chains of residues around it, and also the change in heme stereochemistry has been
reported. The experiments also showed how these structural changes fully reverse as CO rebinds
to the heme16, 17.
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In the present study, molecular dynamic simulations of the CO-bound and CO-unbound
structures of the bjFixLH were performed, modifying the parameters of heme ligation, to
investigate the ligand behavior after CO dissociation as well as the conformations of the protein
before and after ligand dissociation. Simulations were computed in two different environments: a
crystal simulation of a rhombohedral cell containing 18 molecules (Figure 34) and a simulation
of one protein molecule in aqueous solution, with the aim of compare them to experimental
results reported in X-ray time resolved crystallographic studies of this protein17-19. Different
features after CO dissociation were observed in the different simulation environments.
Conformational changes observed in previous experiments by liganded and unliganded structures
of this protein are observed in our simulations but with an important dependence on the location
of the ligand after bond dissociation.

CO Dynamics
Calculations of the distance between the ligand and the heme iron following
dissociation show that the ligand escapes from the heme pocket just 0.13 ns ± 0.04 after the CO
bond is broken in the solution simulations. These results were similar in the three simulations of
the protein performed in the water box. By that time some characteristic structural changes due
to relaxation to the deoxy state can be observed but due to the fast escape the CO behavior inside
the heme pocket was not described with detail.
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Figure 39 Configuration of the Unit Cell of the CO Bound bjFixLH. Eighteen H32 symmetryrelated protein molecules are present. Molecules in blue represent proteins where the CO remains
inside the protein cavity during the complete CO-unbound simulation.

This behavior was different in the MD simulations of the crystal, where 18 proteins are
present in the unit cell. After the bond breaking, the CO stayed within the protein cavity for eight
of the protein molecules during the entire simulation (blue molecules in (Figure 34) whereas for
four other protein molecules the ligand escapes a few fractions of nanosecond after the Fe-CO
bond is removed as in the solution simulations. For the rest of the protein molecules, the CO
escape is observed in between 1 to 10 ns after the bond breaking of the ligand (Figure 35). Our
results show that ~50% of the ligand molecules escape to the solvent at different times in the
CO-unbound crystal simulation.
To study the behavior of the ligand inside the cavity for the eight molecules in which
the CO stays in the binding pocket, analysis of the vector connecting the heme iron atom and the
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ligand was performed. The CO molecule motion was divided into vertical and horizontal
displacements of this vector with respect to the heme plane
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Figure 40 Probability Distribution of CO Remaining near the Heme Pocket during the
Crystal MD Simulations. The CO-Fe bond is broken at 10 ns in our simulations.

Figure 36 shows the average of these displacements for the 8 protein molecules. The
horizontal displacement and fluctuations are greater than the vertical projection. This shows that
the unbound ligand is close to the heme and can interact with some hydrophobic side chains that
point toward the heme: Ile215, Val222, Met234, Leu236 and Ile238.

Structural Changes
The different conformational changes that occur in the protein following the CO
dissociation were studied to compare our simulations to the results reported in previous
experimental work where the bond between the heme iron and the ligand is removed by
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photolysis17. We used vector analysis and determination of distances between different residues
involved in these motions during the simulations.

Figure 41 Displacement of the CO Molecule after Bond Dissociation for the Protein Molecules
in the Crystal Simulations where the CO Remains in the Binding Pocket. Thin line represents the
average horizontal projection of Fe-CO vector onto Fe-CH* vector in the heme plane, Bold line
represents the average vertical projection of Fe-CO vector onto a vector perpendicular to the
heme plane.

Some of the structural changes involve motions of the side chains of amino acids within
the protein that are driven by steric interactions with the ligand. Other motions require the
movement of backbone atoms producing longer-range conformational changes. The protein
regions with more notable conformational changes during the simulations are the Hß and Iß
strands, the FG loop, the heme group, and the Cα and Fα helices (Figure 38).
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Hβ and Iβ Strands
It has been reported that Leu236 located at the Hß strand, must vacate the ligand binding
pocket to accommodate the bound CO16. This involves the shift of the main chain atoms of
Leu236 away from the CO along the Hß strand toward the C-terminus16, 17.
Distance calculations between the side chain of Leu236 and the heme iron show that
there is an average decrease from 7.5 Å to 6.5 Å at the time the CO-Fe bond breaking occurs,
similarly, in the case of Ile238 a decrease was observed from 8.5 Å to 7.25 Å, which is indicative
of the movement of the side chains toward the place where the ligand was present. This distance
reduction is evident in the solution simulations as well as for the four proteins in the crystal
simulations for which the ligand escapes immediately from the heme pocket after CO
dissociation. During the first 10 ns of the run (in which the ligand was bound), that distance is
longer for the side chains of both amino acids, indicating that these residues vacate the place
where CO is located, due to steric interactions present among themselves.
In the case of the protein molecules where the CO remains in the binding pocket after
bond breaking that distance decreases less (about 0.5 Å), due to the presence of the ligand inside
the protein cavity.
Displacement of the Iß strand after release of the ligand is driven by the motion of the side
chain of Leu23617. Hydrogen bonds between Leu236 main chain atoms and the Iß strand residues
Phe252 and Val253, are evident during all the simulations before and after ligand dissociation.
Similarly, Arg254 side chain moves in our simulations as a consequence of a reported structural
domino effect17. But the backbone locations of these amino acids remain mostly unaffected after
ligand dissociation.
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Heme
Displacement of the heme, after the relaxation of the steric hindrance present in the CObound heme and the side chain of Leu236, has also been reported17. This causes the motion of the
heme away from FG loop.
Figure 37 displays the distribution of the distance between the centers of mass of
the FG loop and the heme group. The figure shows that when the CO is bound to the iron atom
this distance distribution is mostly unimodal and centered around 9.2 Å. The distribution is
broader when the CO remains in the cavity after the CO-Fe breaking event. It also shows a shift
of the heme away from the FG loop. Differently, when the ligand escapes the distribution
becomes bimodal with the heme and FG loop coming closer together. The distance between the
heme and the side chain of Phe176 in the Cα helix is a probe of the approach of the heme to the
Cα helix. In the cases where the heme is moving away from the FG loop this distance decreases
from 7.25 Å to 3.97 Å.
Fα helix motion is caused by heme doming and also the motion of the iron out of
movement of the heme plane17. The RMSD of the Fα helix main chain atoms shows an average
increase from 0.43 Å to 1.74 Å during the last 10 ns of the simulation when the CO-Fe bond is
broken and the heme changes its geometry. Heme propionates also show small displacements
during our simulations.
For HP6 the RMSD reaches 1.3Å after the breaking of the CO-Fe bond whereas for HP7
the RMSD fluctuates between two conformations (with RMSD of 0.25 and 1.1 Å) during the
entire simulation including bound and unbound ligand. These variations correspond to the
motion of propionates as a consequence of the heme doming.
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Figure 42 Frequency Distribution of the Distance Separating the Centers of Mass of the FG
Loop and the Heme Group. The solid line represents the distribution of the data in the first 10 ns
(bound ligand). The dashed and dot lines represent the distance distribution for the proteins when
the ligand remains in the cavity and when it escapes, respectively. All the protein conformations
in solution and crystal simulations were included.
FG loop
The FG loop region extends from residue Ser211 to residue Ile215, and its motion after
CO dissociation has been considered a consequence of the heme doming and the motion of the
heme propionate groups, together with the steric interaction between Ile215 and the ligand16.
During our simulations, the motion of the propionate groups drives the motion of the FG loop
through hydrogen bonds formed between these groups and residues in the loop. Specifically,
HP6 forms H-bonds with His214, whereas, HP7 forms H-bonds with Ile215 and Ile216 and a salt
bridge with His214 during the entire simulation. These H-bonds are unaffected by the presence
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or absence of the bond between CO and the iron atom. After CO dissociation, the distance
between Ile215 and the ligand shows an average decrease from 6.63Å to 3.27Å in the case of the
proteins where the ligand remains in the cavity. This indicates an approach of the ligand to this
hydrophobic residue suggesting steric interactions between them that lead to the FG loop motion.
This ligand motion is related to the horizontal displacement observed in Figure 36.
Another of the reported structural changes16 is the motion of the FG loop (residues
His213 to Ile215) towards the place where the heme stays after the removal of the CO-Fe bond
with a corresponding distance increase between residues Ile216 to Ile218 that belong to the Gβ
strand, and the heme pocket. Distance calculations between the residues that belong to the center
of the FG loop (His213 to Ile215) and the heme show a decrease of 1.23Å, in cases where the
ligand escapes from the cavity after bond breaking. The opposite occurs for the eight proteins in
the crystal where the ligand remains inside the cavity during the entire simulation with a distance
increase of 2.16Å. Moreover, the distance from residues Ile216, Ile217 and Ile218 to the heme
increases by an average of 1.58Å, for the cases where the CO escapes from the heme pocket. But
the same distance decreases slightly (an average of 0.55Å) for the rest of the proteins.

Arg220 and Arg206.
Arg220 belongs to the Gß strand and it is considered an important residue in bjFixLH
kinase inactivation mechanism since it stabilizes strong field ligands (O2, CN-), upon ligation by
hydrogen bonds7, 8.
A salt bridge between HP7 O1A and the distal residue Arg220 has been reported as
characteristic of the CO structure regardless the spin state of the heme iron14, 15; these studies
have shown that this salt bridge remains intact in both, the CO-bound and the CO-unbound
75

structures15, 16. However, our results show that this interaction is changing during the duration of
the simulations. Figure 38 shows that when the CO-Fe bond is present the distance distribution
between the O1A of HP7 and NH2 of Arg220 is mostly centered at 3.2Å, which means the salt
bridge is formed. Smaller peaks around 4.8Å indicate the HP7-Arg220 distance oscillates over
time, including larger distances where the salt bridge is not formed. There is a broader
distribution of distances for proteins in which the CO will escape from the protein cavity after
CO dissociation that indicates that the salt bridge was breaking more often for these molecules.
On the other hand after the CO-Fe bond breaking event, in proteins where the ligand stays inside
the cavity the average distance distribution still has a large peak around 3.2Å. The drastic
increase in the distance between O1A and the Arg220 residue in proteins where the ligand
escapes to the solvent is correlated to the CO escape, so this interaction could be coupled to the
onset of the ligand escape.
Arg206 motion has been related to structural changes in Arg220. Arg206 is known to
compensate HP7 when its salt bridge with Arg220 is not present in O2-bound structures8. Still, it
has been reported that Arg206 is bound to HP6 in CN--bound structures7, and its position is more
disordered in CO-bound structures which points to a difference between these the different
ligand-bound structures regarding Arg220 behavior16. Distance calculations show a salt bridge
between Arg206 and HP6 during the CO-bound structure runs, which suggests a similarity to a
strong field ligand in bjFixL, whereas another salt bridge between Arg206 NH1 and HP7 O2A is
formed during the CO-unbound structure simulation just for proteins where the ligand stays
within the cavity which implies that Arg206 compensates HP7 similarly to O2 bound structures.
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Figure 43 Average Frequency Distribution of the Distance between O1A of HP7 and NH2 in the
Basic Residue Arg220 during the Simulation. Salt bridges are within the cutoff distance
(minimal distance) of 3.2Å. Solid and dotted lines represent the first 10ns of the simulation (CO
bound structure) while dashed lines represent the run time period from 10 to 20 ns (unbound
structure). Each distribution is normalized.

It has also been shown that there is a salt bridge and hydrogen bonding between Asp212
and Arg206, characteristic of deoxy structures16. Our simulations show that when the CO-Fe
bond is present, the Arg206-Asp212 salt bridge is forming intermittently and when the CO-Fe
bond is removed this salt bridge is present just for the proteins where the CO escapes. The salt
bridge is broken permanently when the ligand remains within the cavity.

The interaction

between these two residues indicates that FixL relaxes to the deoxy state when CO escapes from
the cavity. Therefore Arg206 interactions depends on ligand behavior
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Relaxation to the Deoxy State
Backbone RMSD between the deoxy crystal structure and the conformations sampled in
our simulations are plotted over time in Figure 39. These plots show that, during the CO-bound
simulation (below 10 ns), there are differences between the proteins configurations; these are
consequence of fluctuations involving mostly motions of the N-terminal helix. In the case of the
CO-unbound simulations (after 10 ns), when the CO remains in the cavity the proteins deviate
more from the deoxy configuration. For proteins with CO escaping events the configurations
approach the deoxy structure as expected.

Structural Changes and Comparison with Experiments
Our crystal simulation results showed that for about 50% of the proteins within the unit
cell the ligand stays within the protein cavity presenting horizontal displacements with respect to
the heme location that lead to steric interactions with hydrophobic residues near the heme. This
suggests that rebinding features could occur for these proteins (in agreement with experiment) 16
while structural relaxation to the deoxy state is observed in proteins where the ligand escapes
completely from the protein framework.
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Figure 44. Backbone RMSD between the Deoxy Structure (PDB entry 1XJ2 28) and the
Conformations Sampled in all the Simulations Plotted over Time. The solid line represents the
results for proteins where the ligand remains in the cavity and the dotted line represents the
results for protein where the ligand escapes. The average standard deviation for both curves is ±
0.39, so deviations of the two curves after bond breaking (10 ns time) are slightly above the
statistical errors.

The side chain of Leu236 has been proposed as a ligand sensing moiety since its motion
toward the hole vacated by CO has been related to the relaxation to the deoxy state whereas the
same residue moves away in the presence of a bound ligand16, 17. Similar changes on the side
chains of Leu236 and Ile238 were observed during our simulations. The side chains of the
residues are closer to the heme iron as the ligand escapes the binding pocket, which points out
the release of their steric interaction with the CO when the ligand is bound to the heme.
However, the propagation of structural changes as a consequence of these motions, through
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hydrogen bonds with residues in the Iß strand is not observed during the duration of our
simulations in contrast to experimental observations17.
Lateral displacement of the heme group was observed during the simulations (Figure 36)
in partial agreement with experimental results17. But we observed that this motion depends on the
location of the CO after the dissociation event. When the ligand remains inside the binding
pocket, the heme moves away from the FG loop and approaches the Cα helix in agreement with
the experimental observations. These changes occur due to steric interactions between the
hydrophobic residue Ile215 in the FG loop and the dissociated ligand. The opposite motions
occur when CO escapes, the absence of these interactions after CO escape makes the heme and
the FG loop approach but only slightly (higher peak in the dotted line distribution of Figure 37).
Averaging the two opposite motions results in a slight lateral increase of the separation between
the heme group and the FG loop as observed in the experiment.
Heme doming and the movement of the iron out of the porphyrin plane after the breaking
of the CO-Fe bond in our simulations lead to the motion of the Fα helix through His200 in
agreement to crystallographic studies17. Furthermore, the relative position of the heme propionate
6 shows variations after ligand dissociation that can be related to heme doming whereas heme
propionate 7 shows smaller fluctuations during all the simulations that are not affected by the
dissociation of the CO. The continuing fluctuations of propionate 7 make the salt bridge between
Arg220 and HP7, characteristic of deoxy and CO-bound structures, break often.
FG loop motion is correlated to heme propionates displacements, due to hydrogen bonds
and salt bridges formed between residues Pro213, His214, Ile215 and Ile216 in the loop and HP6
and HP7. Also, the simulations show an important dependence of the FG loop movement on the
steric interactions with the ligand. From our simulations, when the ligand escapes from the
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protein cavity after dissociation the central portion of the loop moves toward the heme while the
portion of residues Ile216 to Ile218 moves away from the heme as a correlated movement. These
motions were observed in the experiments17. However, motion in the opposite direction occurs
when the ligand remains inside the cavity in our simulations. This motion is not reflected in the
same experiments. The steric interactions between the ligand and Ile215 drive the motion of the
FG loop central portion away from the heme. So, when the ligand stays close to the heme pocket
is inside a “cage” formed by the hydrophobic residues Ile215, Val222, Met234, Leu236 and
Ile238, which keep it there, as it is shown in Figure 40.
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Figure 45 Representation of the Cage-Like Shape Surrounding the CO Ligand of a bjFixLH Protein
Molecule in Crystal Structure.

It also has been shown that there is a relationship between Arg220 and Arg206 dynamics
for O2 bound bjFixL structures8. However, this correlation has not been observed in the case of
the CO bound structure16. In agreement to previous experimental results7, 16, during the CO-bound
structure simulations Arg220-HP7 and Arg206-HP6 salt bridges are present. However, our
81

simulations display different behaviors after dissociation of CO: ligand escape causes the break
of the salt bridge between Arg220 and HP7 whereas Arg206 is interacting with Asp212 by
hydrogen bond, which constitutes a deoxy bjFixL structural feature. When the ligand stays
within the cavity both salt bridges Arg220-HP7 and Arg206-HP7 are forming simultaneously
that indicates that these changes are not mutually exclusive. These observations suggest that the
escape of CO could be related to the increase in distance between Arg220 and O2A in HP7 or the
break of this salt bridge. This makes Arg220 to act as a “gate” in the protein cavity.
Structural changes that have been experimentally demonstrated are observed during our
simulations with important differences depending on the location of the CO after its dissociation.
The fact that the ligand presents different behaviors affects the structural changes observed in the
proteins.

Crystal Unit Cell Deformation
Simulations in the crystal cell using harmonic constraints applied to the protein backbone
were also performed. For these simulations ligand behavior results were similar as before and the
reported structural changes in the protein side chains driven by steric interactions with the ligand,
occurred as well. These similarities indicate that the crystal deformation is not caused by changes
in the shapes of the protein molecules but rather by a change in the packing and water
distribution within the crystal.
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PCA Analysis
PCA result in a set of modes called eigenvectors that represent non-redundant motions in
an MD simulation for a molecule in particular. Every PCA mode is associated with an
eigenvalue; which is defined as the amplitude of fluctuations along that particular mode, each
subsequent mode represents the following largest principal axis of atomic fluctuations
orthogonal to the previous axes20, 21. PCA analysis was done on the trajectory data using the
alpha carbons of each of the 117 residues of the 18 FixL proteins in the unit cell. The results
yielded 3N total modes, where N is the total number of atoms used giving a total of 351 modes
per protein. Using the eigenvalues of the covariance matrix, the calculation of the contribution of
a mode to the total conformational variance was done for our simulation. For all the proteins in
the crystal structure the first mode of motion includes the largest percent of atomic fluctuations
(>96%) represented in the covariance matrix during the CO bound simulations. A small residual
contribution of the second mode also was observed and the rest of the modes slightly contribute
to each residue fluctuations. Figure 41 shows the FixLH average residue fluctuations when the
CO is bound to the proteins along the first PC mode. The results are divided in two dependent on
the final outcome of the ligand after the Fe-CO bond breaking: fluctuations for proteins in which
the ligand remains within the heme pocket and proteins in which the ligand escapes from the
cavity. In the case of the proteins where the ligand stays within the cavity after bond breaking,
variations at residue His162 are observed, also fluctuations around the Fα helix (Ile190 to
Thr210) are important in this case, as well as the large fluctuations observed for residue Asp228
and in the region of the GH loop (~Ser243). Fluctuations are different in the case of the proteins
where the ligand escapes from the heme pocket. The figure shows fluctuations in the region of
the Cα helix (Thr170 to Phe176), also some peaks around the EF loop (Met192 to Asp196).
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Fluctuations within the regions that include the FG loop and the Gβ strand (Thr210 to Lys225),
are also observed. Large fluctuations are observed around residues Leu236 to Thr250 that
corresponds to some residues of the H and I β strands. The region from 255 to 270 corresponds
to the helix at the end of the protein, which is fluctuating indistinctly during all simulations
without any relation to the ligand dynamics. Variations of intrinsic motions of FixL before the
bond-breaking event determines the fate of the ligand after bond rupture. If the residues that
surround the CO are less mobile before the breaking then the ligand has a larger probability to
stay within the heme pocket.
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Figure 46 FixLH Average Residue Fluctuations during the CO Bound Simulation of the Proteins
along the PC1. The data is separated in two (CO escapes or stays) according to the ligand
behavior after bond breaking. For most residues the fluctuations are larger if the final outcome
after bond breaking is for the ligand to escape.
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Ligand Dynamics inside Pocket
Figure 42 shows CO local dynamics within the heme pocket with panels a, b and c
displaying the path of the center of mass of the ligand during the CO unbound simulation22.
Three different scenarios are observed. In the scenario C1 (panels a,d) the CO motion is around
the methine bridge B (CHB) of the heme and it shows contacts between the ligand and the Gβ
and Hβ strands. In the scenario C2 (panels b,e) the ligand remains close to methine bridge A
(CHA) and presents contacts with the Fα helix, the FG loop and the Gβ strand. In the scenario C3
(panels c,f) the ligand moves near the methine bridge C (CHC) and shows contacts with Hβ and
Iβ strands. Therefore three different possible cavities are present inside the heme pocket
according to our simulations. It has been shown through picoseconds mid-infrared spectroscopy
that a cavity within the core of PAS domain adjacent to the heme is present, close to the CHC
methine bridge, which is in agreement with the scenario C323. Probabilities of the ligand
remaining in each cavity are shown in Figure 43. In the figure we are using data for all the
proteins in the crystal structure simulation in which the ligand stays closer to the heme group
immediately after bond breaking. Cavities C1 and C2 present a lower probability of the ligand
remaining closer to them than cavity C3. Both cavities C1 and C2 go closer to zero occupancy
after 17 ns due to ligand escaping to the solvent. But for cavity C3 the ligand tends to remain in
the cavity during the complete simulation time. Therefore our simulations results agree with the
above mid-infrared probe.
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Figure 47 Dynamics of the Ligand. Panels a, b and c show the drawn path of combined
trajectories of the ligand around the heme plane, during the first 5 ns after the CO-Fe bond
remotion. In panels d, e and f the number of contacts between the residues within the protein
region defined in the y-axis and the ligand are shown.
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Figure 48 Probability of the Ligand to Stay inside the Cavities after the Fe-CO Bond Breaking
Event. The probabilities include all the 18 proteins in the crystal simulation (the initial time after
bond breaking do not add up to 100% because for some proteins the ligand escape almost
immediate after the bond is broken or the ligand is outside any of the three cavities).
Probabilities increases (after a slight decrease) are due to ligand motion away cavity area and
subsequent oncoming.

Conclusions
In this work we have performed MD simulations of CO unbounding from the heme
pocket of bjFixLH in aqueous solution and in a crystal cell. Different results after CO
dissociation were observed in the two environments.
For half of the proteins in the crystal simulations the ligand remains inside the binding
cavity during the complete CO-unbound simulation, whereas relaxation to the deoxy state occurs
for those proteins where the carbon monoxide escapes to the solvent and for the aqueous solution
simulation. For the protein where the ligand stays after Fe-CO bond breaking hydrophobic
residues that surround the ligand keep it within the heme pocket in sort of a “cage”.
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Escape of CO is related to the break of the salt bridge between Arg220 and HP7, so
Arg220 is acting as a “gate” of the protein cavity.
Conformational changes observed in previous experiments by liganded and unliganded
structures of this protein are observed in our simulations but with an important dependence on
the location of the ligand after bond dissociation. In turn, the location of the ligand after
dissociation depends on the intrinsic motions and fluctuations of the protein just before the bond
breaking event.
Three possible cavities in the heme plane have been found in our simulations, with cavity
C3 being more effective in keeping the ligand close to the heme group after bond breaking.
Further simulations with enhanced sampling techniques of wild type and mutant species will be
needed to corroborate our findings and suggests new experimental observations to elucidate the
signal transduction pathway of this oxygen sensing enzyme.
Computational Methods
Solution Simulations
Initial coordinates were taken from the 2.4 Å resolution crystal structure of the CO-bound
BjFixLH (PDB entry 1lsv)24, which is the isolated heme-PAS domain of the dimeric oxygen
sensor BjFixL that consists of 130 amino acids. Molecules and structure files were prepared
using VMD program22. Simulations were performed with NAMD 2.6 code25 and CHARMM27
force field26. All the glutamic and aspartic acid residues and the heme prosthetic groups were
taken to be deprotonated while all the lysines and arginines were protonated. The histidine side
chains were modeled as neutral with the δ nitrogen protonated, in order to model a solution at pH
7.5, the pH that was used to prepare the crystals24. Periodic boundary conditions were used
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placing the initial structure in an equilibrated water box of dimensions 68x67x52 Å3. To create a
neutral simulation box, 6 Na+ counterions were added by replacing water molecules at the most
negative electrical potential. The total system size was 1835 protein atoms, 75 heterogen atoms
(heme and ligand), 6 sodium counterions and 6836 TIP3P water molecules, leading to a total of
22424 atoms. The minimization, heating and equilibration of the system were completed during
1100 ps. The system was minimized using the conjugate gradients method, and then was heated
by increments of 0.001K every time step (2fs) up to 287K for 600ps. Next, the system was
equilibrated at constant volume for 400 ps. A standard MD trajectory 10 ns long, at constant
pressure and temperature, was performed with a bound CO, and this was followed for another 10
ns trajectory with unbound CO. The integration time step was 2fs, van der Waals interactions
were calculated every step (2fs) while electrostatics interactions were calculated every other step
(PME every 4fs), using the multiple time step method employed by NAMD (Verlet-I/rRESPA/Impulse MTS Method)27. The Particle Ewald Mesh summation for long range
electrostatic interactions was used with the number of grid points of 64(26) in the x, y and z
dimensions accordingly with the periodic box size. The cutoff distance for van der Waals was
12Å. A non-bonded pair list cutoff of 13.5Å and the pairlist was updated every 10 time steps.
The pressure was controlled using the Nosé-Hoover Langevin piston pressure control25. The first
10 ns of each run were performed using force-field parameters for a six-coordinated heme while
for the final 10 ns domed, five-coordinate heme force field parameters were used28, 29. Atomic
coordinates were stored every 1ps for data analysis. Three different simulation replicates were
computed.
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Crystal Simulation
The starting coordinates for this simulation was the crystal structure of the CO-bound
BjFixL heme domain. This crystal belongs to the H32 space group, with the following
rhombohedral cell parameters a=b=127.01Å, c=58.14Å, α=β= 90°, γ=120°20. The H32 crystal
unit cell contains 18 symmetry related molecules; therefore the initial coordinates of the crystal
unit cell were obtained by applying the H32 symmetry transformation30. The 18 proteins were
hydrated by placing 684 water molecules at crystallographic sites and 16116 at
noncrystallographic sites31, in order to have a box density close to the experimental value
(59.31%v/v). A total of 107 Na+ counterions replaced water molecules at the most
electronegative potential sites to get a neutral simulation box. The number of protein atoms was
33030, heterogen atoms 1350, 48027 atoms from water molecules and 107 sodium atoms for a
total number of 82514 atoms. Basically the same protocol described for the solution simulations
was employed for the crystal unit cell run. The solvent was relaxed by energy minimization and
brought to a temperature of 287K assigning increments of 0.001K every time step (2fs), during a
700ps run while restraining the protein, heme and CO initial positions with a harmonic potential.
The system was then minimized gradually lowering the restraining force constant to zero during
four 100ps runs and heated to 287K without restraints. The same process as of minimization was
employed for the system equilibration at constant volume in a stepwise manner equilibrating the
solvent and then the complete system. A 20 ns MD run was done at constant P and T, with the
same parameters used in the solution simulation. A feature observed during previous simulations
(that we also observe in the simulations we are reporting here) was the deformation of the unit
cell. Previous crystal molecular dynamics simulations, at constant volume and pressure, have
shown that these simulations are sensitive to several model parameters that lead to smaller
90

distortions in shape and size18. In order to study the effect of these deformations in our crystal
simulations, an additional simulation using harmonic constraints applied to the proteins
backbone was done.
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